WO2024251939A3 - Ccr1 modulators and methods of use - Google Patents

Ccr1 modulators and methods of use Download PDF

Info

Publication number
WO2024251939A3
WO2024251939A3 PCT/EP2024/065720 EP2024065720W WO2024251939A3 WO 2024251939 A3 WO2024251939 A3 WO 2024251939A3 EP 2024065720 W EP2024065720 W EP 2024065720W WO 2024251939 A3 WO2024251939 A3 WO 2024251939A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
terminal portion
amino acid
seq
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2024/065720
Other languages
French (fr)
Other versions
WO2024251939A2 (en
Inventor
Fabrice CERINI
Marianne PAOLINI-BERTRAND
Ganesh Kumar MOTHUKURI
Nicolas CALO
Irène ROSSITTO-BORLAT
Simona ANGERANI
Oliver Hartley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite de Geneve
Original Assignee
Universite de Geneve
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite de Geneve filed Critical Universite de Geneve
Publication of WO2024251939A2 publication Critical patent/WO2024251939A2/en
Publication of WO2024251939A3 publication Critical patent/WO2024251939A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The disclosure provides polypeptides, peptides, and conjugates relating to CCL3 N-terminal variants comprising an N-terminal portion and a C-terminal portion, wherein the N-terminal portion comprises an amino acid sequence with 0, 1, 2, 3, 4, 5, or 6 amino acid substitutions relative to any one of SEQ ID NO: 3-86, and wherein the C-terminal portion comprises an amino acid sequence at least 70% identical to SEQ ID NO: 2, and methods of use thereof.
PCT/EP2024/065720 2023-06-09 2024-06-07 Ccr1 modulators and methods of use Ceased WO2024251939A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363507297P 2023-06-09 2023-06-09
US63/507,297 2023-06-09

Publications (2)

Publication Number Publication Date
WO2024251939A2 WO2024251939A2 (en) 2024-12-12
WO2024251939A3 true WO2024251939A3 (en) 2025-01-16

Family

ID=91530190

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2024/065720 Ceased WO2024251939A2 (en) 2023-06-09 2024-06-07 Ccr1 modulators and methods of use

Country Status (1)

Country Link
WO (1) WO2024251939A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993013206A1 (en) * 1991-12-23 1993-07-08 British Bio-Technology Limited Stem cell inhibiting proteins
US20040197303A1 (en) * 2002-09-13 2004-10-07 Ahmed Merzouk Design of chemokine analogs for the treatment of human disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993013206A1 (en) * 1991-12-23 1993-07-08 British Bio-Technology Limited Stem cell inhibiting proteins
US20040197303A1 (en) * 2002-09-13 2004-10-07 Ahmed Merzouk Design of chemokine analogs for the treatment of human disease

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE UNIPROT [online] 22 February 2023 (2023-02-22), "Uncharacterized protein", XP093207844, retrieved from https://rest.uniprot.org/unisave/A0A6A6FF96?format=txt&versions=7 Database accession no. A0A6A6FF96 *
MENTEN P ET AL: "THE LD78BETA ISOFORM OF MIP-1ALPHA IS THE MOST POTENT CCR5 AGONIST AND HIV-1-INHIBITING CHEMOKINE", THE JOURNAL OF CLINICAL INVESTIGATION, B M J GROUP, vol. 104, no. 4, 1 August 1999 (1999-08-01), pages R01 - R05, XP000867805, DOI: 10.1172/JCI7318 *
NIBBS R J B ET AL: "LD78beta, anon-allelic variant of human MIP-1alpha (LD78alpha), has enhanced receptor interactions and potent HIV suppressive activity", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 274, no. 25, 18 June 1999 (1999-06-18), pages 17478 - 17483, XP002129767, ISSN: 0021-9258, DOI: 10.1074/JBC.274.25.17478 *

Also Published As

Publication number Publication date
WO2024251939A2 (en) 2024-12-12

Similar Documents

Publication Publication Date Title
NZ624533A (en) Novel immunotherapy against several tumors including neuronal and brain tumors
WO2007094916A3 (en) Non-natural amino acid polypeptides having modulated immunogenicity
MX353234B (en) Polypeptide variants with altered effector function.
WO2005068494A3 (en) Chimera botulinum toxin type e
NZ600732A (en) Oxyntomodulin peptide analogue
NZ627111A (en) Variants of activin iib receptor polypeptides and uses thereof
NZ597685A (en) Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
HRP20090245T1 (en) Pyy agonists and uses thereof
NZ600690A (en) Fkbp-l and uses thereof
IN2014CN02050A (en)
AR072009A1 (en) MUTANTS OF THE GROWTH FACTOR OF FGF21 FIBROBLASTS AND USES OF THE SAME
UA103215C2 (en) Polypeptide with xylanase activity
WO2009069808A1 (en) Epha4 polypeptide having novel activity and use thereof
WO2010126156A3 (en) Alkaline protease variants
WO2023250384A3 (en) Crispr-cas effector polypeptides and methods of use thereof
ZA200901342B (en) Cytokine derivatives
GEP20115196B (en) Neublastin variants
WO2004005317A3 (en) Thrombin peptide derivative dimers
WO2024251939A3 (en) Ccr1 modulators and methods of use
TW200505943A (en) Polypeptide
DK1519951T3 (en) Cationic straight chain peptides with antifungal properties
NZ591827A (en) Biologically active peptides comprising PTTKTYFPHF and their uses in the manufacture of a medicament for modulating immune reaction in a radiotherapy-induced immuno-compromised subject
WO2006097432A3 (en) Keratin-binding desmoplakin polypeptide sequences
WO2019152418A3 (en) Anti-inflammatory compounds and methods of use
WO2022133333A3 (en) Compositions and method of use for hair straightening and shaping

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24732570

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE